HalfLifeDBEvidence before certainty.

AL-LAD evidence profile

The cited AL-LAD record is analytical: it helps establish identity and impurities, not human elimination.

Category: psychedelic · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model statusNo curve publishedCurrent sources do not support one defensible human input
Evidence boundarySource note onlyNo animal, forensic, mixture, or proxy value is presented as a human half-life
Model scopeNot modeledThe profile explains what the available records can and cannot establish
References2Linked studies, labels, reviews, or identity records described below

AL-LAD: evidence and interpretation notes

Why HalfLifeDB does not plot AL-LAD

The cited AL-LAD record is analytical: it helps establish identity and impurities, not human elimination. No representative curve is shown until a direct human pharmacokinetic record can support the input.

What each source contributes

  • PubChem: AL-LAD. This identity record confirms names and compound identity and does not supply a human half-life.
  • Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities. This supporting literature record adds compound-specific background and is used only within the limits of its design.

For AL-LAD, the decision to withhold a curve turns on the limits visible in Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities. This supporting literature record adds compound-specific background, but it is used only within the limits of its design.

What evidence would change the page

Before AL-LAD could move from an evidence note to a chart, a study would need serial human measurements of the parent compound after a defined route, enough sampling to characterize elimination, and a population narrow enough to label honestly. That is a different evidence package from Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities.

InterpretationCategory context and evidence limits

psychedelic context

Psychedelic duration is shaped by pharmacodynamics as well as pharmacokinetics, so subjective effects may not track a simple elimination curve.

  • The curve does not predict psychological effects or functional safety.
  • Metabolites and downstream receptor activity are not separately modeled.
  • Published estimates may come from small or specialized study populations.
EvidenceSource trail and model decision

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

1 PubMed0 PMC0 DailyMed1 PubChem
  1. Identity record PubChem Compound Summary: AL-LAD.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
  2. Research abstract PubMed: Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities.
    Synthesis or clinical background source used to frame the evidence and its limits rather than to create a new measured value.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.